Provider Briefing: Cefepime Supply Remains Constrained in 2026

The Cefepime injection shortage continues to affect hospital systems and outpatient infusion services across the United States in 2026. For providers managing patients with serious bacterial infections — particularly febrile neutropenia, hospital-acquired pneumonia, and complicated UTIs — this shortage creates real prescribing challenges that impact patient outcomes.

This briefing covers the current supply picture, the timeline of the shortage, prescribing considerations, alternatives, cost implications, and tools to help your patients access treatment.

Shortage Timeline

Cefepime injection has experienced recurring supply disruptions since the early 2010s, reflecting broader vulnerabilities in the sterile injectable manufacturing sector:

• 2010-2015: Initial shortages driven by manufacturing quality issues at key facilities, including FDA warning letters and production line shutdowns
• 2016-2019: Periodic recovery followed by recurrence as manufacturers struggled to maintain consistent production
• 2020-2022: COVID-19 pandemic exacerbated supply chain stress, increased hospital demand for IV antibiotics, and disrupted raw material sourcing
• 2023-2024: Shortages intensified as multiple sterile injectable manufacturers experienced simultaneous production issues. ASHP listed Cefepime as a current shortage throughout this period.
• 2025-2026: B. Braun reports ongoing manufacturing delays. Other manufacturers (Baxter, Apotex, Hospira) continue to experience intermittent disruptions. The FDA is actively engaged with manufacturers but no firm resolution timeline has been announced.

Prescribing Implications

The ongoing shortage has several direct implications for clinical practice:

Antimicrobial Stewardship Pressure

Hospital antimicrobial stewardship programs (ASPs) are increasingly required to balance optimal empiric therapy against available supply. This creates tension between evidence-based guidelines (which may recommend Cefepime as first-line) and practical availability.

Providers should coordinate with their ASP and pharmacy team to understand real-time institutional availability before writing empiric orders. Many institutions have implemented shortage-specific order sets or formulary substitution protocols.

Dose Adjustment Considerations

The FDA issued a Drug Safety Communication regarding Cefepime-associated neurotoxicity, particularly seizures, in patients with renal impairment who do not receive appropriate dose adjustments. In shortage situations where patients may be transitioned between facilities or providers, ensuring accurate renal dose adjustments is critical.

Standard dose adjustments for creatinine clearance (CrCl) ≤60 mL/min should be rigorously followed. Up to 15% of ICU patients receiving Cefepime may experience neurotoxic effects, with risk factors including advanced age, renal dysfunction, and pre-existing neurological conditions.

For a patient-facing overview of side effects, see: Cefepime side effects: What to expect.

Culture-Directed Therapy

When Cefepime supply is constrained, the importance of obtaining cultures before initiating empiric therapy increases. Culture-directed de-escalation can allow transition to narrower-spectrum agents, preserving limited Cefepime supply for patients who truly need it.

Current Availability Picture

Supply varies significantly across health systems, geographic regions, and distributor networks. Key observations:

• Pre-mixed solutions (1g/50mL, 2g/100mL) have been more consistently affected than powder vials in some markets
• Larger health systems with GPO (Group Purchasing Organization) contracts and multiple distributor relationships generally fare better
• Outpatient infusion and home infusion services may face disproportionate impact due to their position in the supply chain hierarchy
• Specialty distributors may have intermittent availability that mainstream distributors lack

For real-time availability tracking, Medfinder for Providers helps clinicians locate medications across pharmacy networks.

Cost and Access Implications

Although Cefepime is available as a generic, the shortage has contributed to pricing volatility:

• Hospital acquisition cost: Has fluctuated significantly during shortage periods, with some facilities reporting 2-3x normal pricing during peak shortages
• Patient out-of-pocket for outpatient IV therapy: Cash prices range from approximately $200 to $600+ per treatment course; discount services like SingleCare list prices as low as $93 for a 9-vial course
• Insurance coverage: Generally covered under medical benefits (not pharmacy benefits) when administered in healthcare facilities or through home infusion. Prior authorization is not typically required given the medically necessary indication, though some payers may require documentation.

Providers managing patients with cost barriers should explore patient assistance resources through NeedyMeds and RxAssist.

Alternative Agents

When Cefepime is unavailable, the following empiric alternatives should be evaluated based on suspected organisms, local antibiogram data, and patient-specific factors:

Piperacillin/Tazobactam (Zosyn)

• Comparable broad-spectrum gram-negative coverage with added anaerobic activity
• Standard dose: 3.375-4.5 g IV every 6-8 hours
• Consider: Also subject to periodic shortages; AKI risk when combined with Vancomycin has been debated but warrants monitoring

Meropenem (Merrem)

• Broadest-spectrum option; effective against most ESBL-producing and AmpC-producing organisms
• Standard dose: 1-2 g IV every 8 hours
• Consider: Carbapenem-sparing strategies are important for stewardship; reserve for confirmed or highly suspected resistant organisms

Ceftazidime (Fortaz)

• Third-generation cephalosporin with anti-Pseudomonal activity
• Standard dose: 1-2 g IV every 8 hours
• Consider: Weaker gram-positive coverage than Cefepime; may need supplementation with gram-positive agent depending on clinical scenario

Ceftazidime/Avibactam (Avycaz)

• Enhanced coverage against KPC-producing and some OXA-48-producing organisms
• Consider: Significantly more expensive; appropriate for documented or suspected CRE infections

For a detailed comparison accessible to patients, see: Alternatives to Cefepime.

Tools and Resources for Providers

• Medfinder for Providers — Search for medication availability across pharmacy and facility networks
• ASHP Drug Shortage Resource Center — Current shortage listings, management strategies, and manufacturer updates
• FDA Drug Shortage Database — Official FDA shortage listings and communications
• Institutional ASP teams — Work with your antimicrobial stewardship pharmacist to develop shortage-specific protocols and order sets

Looking Ahead

The structural issues driving Cefepime shortages — limited manufacturing capacity, thin margins for sterile injectables, and consolidated supply chains — are unlikely to resolve quickly. Federal initiatives including the DRUGS Act and FDA efforts to incentivize sterile injectable manufacturing may provide medium-term relief, but providers should plan for continued intermittent shortages through 2026 and beyond.

Developments to watch:

• New manufacturer entries into the Cefepime generic market
• FDA authorization of imports during shortage periods
• Expansion of extended-infusion and continuous-infusion Cefepime protocols to optimize limited supply
• Broader adoption of Cefepime/Enmetazobactam (Exblifep) for resistant infections

Final Thoughts

The Cefepime shortage requires providers to balance evidence-based care with supply realities. Close coordination between clinicians, pharmacists, and antimicrobial stewardship teams is essential. Leverage tools like Medfinder for Providers to help your patients access treatment, and stay current with ASHP and FDA updates as the supply picture evolves.

For patient-facing resources you can share, see: Cefepime shortage: What patients need to know and How to find Cefepime in stock near you.